# Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

> **NCT00143975** · PHASE2 · COMPLETED · sponsor: **University of Ulm** · enrollment: 95 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Gemtuzumab Ozogamicin
- **DRUG:** All-trans-Retinoid Acid

## Key facts

- **NCT ID:** NCT00143975
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-07
- **Final completion:** 2009-06
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2010-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143975, "Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00143975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*